No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins

被引:67
作者
Tateishi, T [1 ]
Watanabe, M
Moriya, H
Yamaguchi, S
Sato, T
Kobayashi, S
机构
[1] St Marianna Univ, Sch Med, Dept Pharmacol, Kanagawa 2168511, Japan
[2] St Marianna Univ, Sch Med, Dept Surg 1, Kanagawa 2168511, Japan
[3] Biomed Res Inst, HAB Discuss Grp, Chiba, Japan
关键词
nifedipine oxidation activity; CYP3A4; CYP3A5; CYP3A7; hepatic microsomes; ethnic difference; Japanese; Caucasian;
D O I
10.1016/S0006-2952(98)00375-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ethnic differences in the pharmacokinetics of nifedipine, a substrate of CYP3A, and in CYP3A7 expression have been reported. The aim of the present study was to measure the protein levels of CYP3A4, CYP3A5, and CYP3A7 and nifedipine oxidation activity in hepatic microsomes from 15 Caucasian and 15 Japanese patients for comparison between the two ethnic groups. Nifedipine oxidation activity and CYP3A4 protein level were well correlated. No significant difference between Caucasian and Japanese microsomal samples was found in nifedipine oxidation activity or in the CYP3A4 protein level. CYP3A5 was detected in 6 of 15 Caucasian samples and in 5 of 15 Japanese samples, but no ethnic difference was found in either the frequency of expression or its protein level. CYP3A7 was found in 10 of 15 Caucasian samples and in 14 of 15 Japanese samples. Although the estimated CYP3A7 protein level was higher in the Japanese than in the Caucasian samples, its protein level was much lower than that of CYP3A4. These results imply that the contribution of CYP3A5 or CYP3A7 to the purported Caucasian-Japanese ethnic difference in the overall CYP3A activity seems to be small. BIOCHEM PHARMACOL 57;8:935-939, 1999. (C) 1999 Elsevier Science Inc.
引用
收藏
页码:935 / 939
页数:5
相关论文
共 27 条
[1]   ETHNIC-DIFFERENCES IN THE PHARMACOKINETICS OF ORAL NIFEDIPINE [J].
AHSAN, CH ;
RENWICK, AG ;
MACKLIN, B ;
CHALLENOR, VF ;
WALLER, DG ;
GEORGE, CF .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (04) :399-403
[2]  
AOYAMA T, 1989, J BIOL CHEM, V264, P10388
[3]  
Daly D. A., 1993, American Journal of Speech-Language Pathology, V2, P6, DOI [10.1044/1058-0360.0202.06, DOI 10.1044/1058-0360.0202.06]
[4]   THE GENETIC-POLYMORPHISM OF DEBRISOQUINE SPARTEINE METABOLISM - CLINICAL ASPECTS [J].
EICHELBAUM, M ;
GROSS, AS .
PHARMACOLOGY & THERAPEUTICS, 1990, 46 (03) :377-394
[5]   Expression of cytochrome P450 3A7 in Escherichia coli: Effects of 5' modification and catalytic characterization of recombinant enzyme expressed in bicistronic format with NADPH-cytochrome P450 reductase [J].
Gillam, EMJ ;
Wunsch, RM ;
Ueng, YF ;
Shimada, T ;
Reilly, PEB ;
Kamataki, T ;
Guengerich, FP .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1997, 346 (01) :81-90
[6]  
Guengerich F. Peter, 1995, P473
[7]   ESTIMATION OF ISOZYMES OF MICROSOMAL CYTOCHROME-P-450 IN RATS, RABBITS, AND HUMANS USING IMMUNOCHEMICAL STAINING COUPLED WITH SODIUM DODECYL-SULFATE POLYACRYLAMIDE-GEL ELECTROPHORESIS [J].
GUENGERICH, FP ;
WANG, P ;
DAVIDSON, NK .
BIOCHEMISTRY, 1982, 21 (07) :1698-1706
[8]  
GUENGERICH FP, 1991, J PHARMACOL EXP THER, V256, P1189
[9]  
GUENGERICH FP, 1986, J BIOL CHEM, V261, P391
[10]   IMMUNOCHEMICAL STUDIES FOR THE PRESENCE OF P-450 HFLA, A FORM OF CYTOCHROME-P-450 IN HUMAN-FETAL LIVERS IN HUMAN HEPATOCELLULAR-CARCINOMA CELLS [J].
KITADA, M ;
TSUKIDATE, K ;
TAKEUCHI, J ;
TANEDA, M ;
KOMORI, M ;
OHI, H ;
ITAHASHI, K ;
KAMATAKI, T .
JOURNAL OF PHARMACOBIO-DYNAMICS, 1989, 12 (06) :341-344